Graphite Bio is a clinical-stage, next-generation gene editing company focused on developing curative therapies for patients who have serious, life-threatening genetic diseases. The company’s platform harnesses the natural cellular process of homology directed repair (HDR) and targeted DNA integration to precisely repair genetic defects at their source. Graphite Bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients’ lives.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $195.75M
Founded date: 2020
Investors 2
| Date | Name | Website |
| 17.08.2021 | Logos Capi... | logoscapit... |
| - | RA Capital... | racap.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.09.2020 | Series A | $45M | - |
| - | Series B | $150.75M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Jo | Viney | Board of D... | linkedin.c... | - | - |
Mentions in press and media 12
| Date | Title | Description |
| 15.11.2023 | The apparently strong correlation between biotech stocks and the price of eggs, explained | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with some annoyingly good news for the biotech market, a look at the plight of the Ph.D... |
| 06.01.2023 | A tiny biotech just suffered a safety scare in a gene-editing trial, raising 3 big questions for the entire CRISPR field | Graphite Bio CEO Josh Lehrer Graphite Bio This story is available exclusively to Insider subscribers. Become an Insider and start reading now. The first patient treated with Graphite Bio's gene-editing program suffered a serious side effect... |
| 25.06.2021 | With sickle cell disease study in sight, Graphite Bio draws up a $238M IPO | Graphite Bio’s technology precisely finds and replaces genes, offering potential cures for genetic diseases. The gene-editing biotech is preparing to bring its most advanced therapeutic candidate into human testing later this year and its I... |
| 15.03.2021 | Graphite Bio : Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies | Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the close of an oversubscribed $150 million Series B financing. The company ... |
| 15.03.2021 | Graphite Bio, Inc. announced that it has received $150.749985 million in funding from a group of investors | On March 15, 2021, Graphite Bio, Inc. closed the transaction. The company has received funding in series B round of funding led by Rock Springs Capital Management LP and new investor RA Capital Management, L.P. The transaction also included... |
| 15.03.2021 | Daily funding roundup - March 15th, 2021 | Stripe landed $600M; ElevateBio raised $525M; Graphite Bio secured $150M Airtable: Airtable is a San Francisco-based no-code relational database that has amassed a customer base that spans 250,000 different organizations. Airtable just clos... |
| 24.02.2021 | Graphite Bio Expands Leadership Team with Appointment of Jerry Cacia as Chief Technical Officer | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 24, 2021-- Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointment... |
| 16.09.2020 | Gene-editing biotech startup Graphite Bio launches with $45 million Series A funding to treat a broad range of severe diseases | CRISPR-Cas9 gene editing has transformed the biotechnology landscape due to its ability to specifically induce double-stranded DNA breaks that can disrupt genes or genetic control regions, leading to novel treatment approaches for a range o... |
| 16.09.2020 | Graphite Bio Launches with $45M Series A | SOUTH SAN FRANCISCO, CA, Graphite Bio announced a $45 million Series A financing led by founding investor Versant Ventures. >> Click here for more funding data on Graphite Bio >> To export Graphite Bio funding data to PDF an... |
| - | Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 15, 2021-- Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the close of an... |
Show more